Something to reassure parents. The first doses of the preventive treatment against bronchiolitis will be delivered “this Thursday” in pharmacies, declared this Tuesday morning the president of Sanofi France, Audrey Duval, on the set of BFM Business. “We will have 600,000 doses ready” for the entire 2024-2025 season, said the leader of the French pharmaceutical group, who spoke at the French Entrepreneurs’ Meeting (Ref), the Medef summer university.
Tested on a large scale last winter in several countries, including France, the Beyfortus treatment developed by Sanofi is a preventive treatment against bronchiolitis. Close to a vaccine, this treatment has made it possible to avoid a large number of hospitalisations of babies. Bronchiolitis affects many babies every winter, who are affected for days by respiratory problems. These are generally not serious, but can lead to hospitalisation.
Other treatments
There are other treatments, such as GSK’s Arexvy vaccine and Moderna’s recently approved vaccine by the European Union, that target older people, in whom the risks of RSV are less well known, although it can cause sometimes fatal complications. A fourth preventive treatment, Pfizer’s Abrysvo, is aimed at both categories: young children and the elderly.
Source: BFM TV
